• Explore /
  • Poster
  • / Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.

Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.

Abstract Poster

Authors

null

M. Simonelli

Humanitas Cancer Center, Rozzano, Italy

M. Simonelli , P. A. Zucali , R. De Sanctis , E. Lorenzi , F. De Vincenzo , L. Rimassa , M. C. Tronconi , N. Personeni , G. Masci , M. Zuradelli , M. Perrino , M. Bertossi , L. Giordano , A. Santoro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT00984425

Citation

J Clin Oncol 29: 2011 (suppl; abstr 2521)

Abstract #

2521

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Sarina Anne Piha-Paul

First Author: Philippe L. Bedard

First Author: Christian K. Kollmannsberger

Poster

2013 ASCO Annual Meeting

A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.

A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.

First Author: Kari Braun Wisinski